4234 related articles for article (PubMed ID: 36274602)
41. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
[TBL] [Abstract][Full Text] [Related]
42. Association of Prior Vaccination With Influenza Vaccine Effectiveness in Children Receiving Live Attenuated or Inactivated Vaccine.
McLean HQ; Caspard H; Griffin MR; Gaglani M; Peters TR; Poehling KA; Ambrose CS; Belongia EA
JAMA Netw Open; 2018 Oct; 1(6):e183742. PubMed ID: 30646262
[TBL] [Abstract][Full Text] [Related]
43. A 1-year follow-on study from a randomised, head-to-head, multicentre, open-label study of two pandemic influenza vaccines in children.
de Whalley P; Walker W; Snape MD; Oeser C; Casey M; Moulsdale P; Harrill C; Andrews N; Hoschler K; Thompson B; Jones C; Chalk J; Kerridge S; Tomlinson R; Heath PT; Finn A; Faust S; Miller E; Pollard AJ
Health Technol Assess; 2011 Dec; 15(45):v-vi, xi-xiii, 1-128. PubMed ID: 22257497
[TBL] [Abstract][Full Text] [Related]
44. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
45. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
[TBL] [Abstract][Full Text] [Related]
46. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England.
Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M
BMC Med; 2017 Sep; 15(1):166. PubMed ID: 28882149
[TBL] [Abstract][Full Text] [Related]
47. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 Months to 8 Years Old During 2011-2012 and 2012-2013: The Importance of Two Priming Doses.
Thompson MG; Clippard J; Petrie JG; Jackson ML; McLean HQ; Gaglani M; Reis EC; Flannery B; Monto AS; Jackson L; Belongia EA; Murthy K; Zimmerman RK; Thaker S; Fry AM
Pediatr Infect Dis J; 2016 Mar; 35(3):299-308. PubMed ID: 26658375
[TBL] [Abstract][Full Text] [Related]
48. Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2015-2016.
Gemmill I;
Can Commun Dis Rep; 2015 Oct; 41(10):227-232. PubMed ID: 29769917
[TBL] [Abstract][Full Text] [Related]
49. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
[TBL] [Abstract][Full Text] [Related]
50. Protection of children against influenza: Emerging problems.
Principi N; Esposito S
Hum Vaccin Immunother; 2018 Mar; 14(3):750-757. PubMed ID: 28129049
[TBL] [Abstract][Full Text] [Related]
51. Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Pepin S; Dupuy M; Borja-Tabora CFC; Montellano M; Bravo L; Santos J; de Castro JA; Rivera-Medina DM; Cutland C; Ariza M; Diez-Domingo J; Gonzalez CD; Martinón-Torres F; Papadopoulou-Alataki E; Theodoriadou M; Kazek-Duret MP; Gurunathan S; De Bruijn I;
Vaccine; 2019 Mar; 37(13):1876-1884. PubMed ID: 30558818
[TBL] [Abstract][Full Text] [Related]
52. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.
Piedra PA; Gaglani MJ; Riggs M; Herschler G; Fewlass C; Watts M; Kozinetz C; Hessel C; Glezen WP
Pediatrics; 2005 Sep; 116(3):e397-407. PubMed ID: 16140685
[TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial.
Vesikari T; Virta M; Heinonen S; Eymin C; Lavis N; Chabanon AL; Gresset-Bourgeois V
Hum Vaccin Immunother; 2020 Mar; 16(3):623-629. PubMed ID: 31526225
[TBL] [Abstract][Full Text] [Related]
54. [Choice of influenza vaccine in people over 65 years old. Analysis of reports from international vaccination advisory committees].
Pérez-Rubio A; Castrodeza JJ; Eiros JM
Rev Esp Quimioter; 2021 Dec; 34(6):631-638. PubMed ID: 34545737
[TBL] [Abstract][Full Text] [Related]
55. Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009.
;
MMWR Recomm Rep; 2009 Aug; 58(RR-10):1-8. PubMed ID: 19713882
[TBL] [Abstract][Full Text] [Related]
56. Enhanced passive safety surveillance of three marketed influenza vaccines in the UK and the Republic of Ireland during the 2017/18 season.
Gandhi-Banga S; Chabanon AL; Eymin C; Caroe T; Butler K; Moureau A
Hum Vaccin Immunother; 2019; 15(9):2154-2158. PubMed ID: 30897026
[TBL] [Abstract][Full Text] [Related]
57. Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons.
Lu PJ; Santibanez TA; Williams WW; Zhang J; Ding H; Bryan L; O'Halloran A; Greby SM; Bridges CB; Graitcer SB; Kennedy ED; Lindley MC; Ahluwalia IB; LaVail K; Pabst LJ; Harris L; Vogt T; Town M; Singleton JA;
MMWR Surveill Summ; 2013 Oct; 62(4):1-28. PubMed ID: 24157710
[TBL] [Abstract][Full Text] [Related]
58. Summary of the National Advisory Committee on Immunization (NACI) Statement on Seasonal Influenza Vaccine for 2016-2017.
Gemmill I; Zhao L; Cochrane L;
Can Commun Dis Rep; 2016 Sep; 42(9):188-192. PubMed ID: 29770030
[TBL] [Abstract][Full Text] [Related]
59. Summary of the NACI Seasonal Influenza Vaccine Statement for 2019-2020.
Zhao L; Young K; Gemmill I
Can Commun Dis Rep; 2019 Jun; 45(6):149-155. PubMed ID: 31285706
[TBL] [Abstract][Full Text] [Related]
60. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015.
Flannery B; Clippard J; Zimmerman RK; Nowalk MP; Jackson ML; Jackson LA; Monto AS; Petrie JG; McLean HQ; Belongia EA; Gaglani M; Berman L; Foust A; Sessions W; Thaker SN; Spencer S; Fry AM;
MMWR Morb Mortal Wkly Rep; 2015 Jan; 64(1):10-5. PubMed ID: 25590680
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
